The number of Alzheimer’s cases continues to grow, with the number of people living with the disease doubling every five years.
By 2060, researchers expect the number of people living with Alzheimer’s to nearly triple to 14 million people.
The FDA recently announced the approval of a new medication to target the proteins that interfere with the transmission of nerve impulses.
The announcement comes hot on the heels of recent news about a synthetic peptide that may reduce the production of these proteins.
Fox News reports on the new drug, the first of its kind:
The U.S. Food and Drug Administration (FDA) has approved a new medication for people with Alzheimer’s disease.
Eli Lilly’s Kisunla (donanemab) is a once-monthly injection intended for adults with early symptomatic Alzheimer’s disease, according to a press release from the company.
Eligible patients include those with mild cognitive impairment (MCI) and those who have mild dementia with confirmed amyloid pathology.
This is the first medication to target amyloid plaques — the proteins that build up in the brains of Alzheimer’s patients, often impairing memory and cognitive function — with evidence to support stopping therapy when amyloid plaques are removed, the release stated.
“Once-monthly Kisunla is the first and only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed,” an Eli Lilly and Company spokesperson told Fox News Digital in an email.
